在乳腺癌延长辅助内分泌治疗中的精密药物
1Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Current opinion in oncology
|August 25, 2023
概括
基因组测试有助于选择激素受体阳性乳腺癌患者进行延长内分泌治疗. 这些测试评估晚期复发风险,指导治疗决策,以平衡益处和毒性.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 内分泌学 在内分泌学.
背景情况:
- 激素受体阳性乳腺癌患者面临晚期复发风险,即使经过5年的内分泌治疗.
- 延长内分泌疗法可以防止晚期复发,但具有毒性和可变的益处.
- 在延长辅助内分泌治疗中,最佳的患者选择至关重要.
研究的目的:
- 审查基因组测试在选择患者进行早期乳腺癌延长辅助内分泌疗法的作用.
- 讨论可用的基因组测试对晚期复发的预后性能.
- 评估基因组测试在指导扩展内分泌治疗决策中的有用性.
主要方法:
- 对研究基因组测试的预后性能的研究的综述 (型DX,BCI,Prosigna,EndoPredict).
- 对预测晚期复发和从延长内分泌治疗中获益的数据的分析.
- 对风险分层和治疗个性化的临床实用性的评估.
主要成果:
- 基因组测试显示,在预测临床病理因素之外的晚期复发风险方面,结果各不相同.
- 乳腺癌指数 (BCI) 已经显示出预测延长内分泌治疗的益处的潜力.
- 对于BCI的数据限制,需要对常规临床使用进行进一步调查.
结论:
- 基因组测试是不断发展的工具,有助于选择患者进行扩展内分泌治疗.
- 这些测试旨在通过识别受益最多的患者来个性化治疗.
- 需要进一步验证,以优化基因组测试在临床实践中的使用.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


